A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis
暂无分享,去创建一个
J. Erälinna | I. Mononen | E. Lilius | I. Laitinen | M. Soilu-Hänninen | M. Laaksonen | J. Erälinna
[1] A. Ascherio,et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.
[2] G. Rice,et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[3] L. Airas,et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis , 2005, Multiple sclerosis.
[4] P. Lips,et al. Estimates of optimal vitamin D status , 2005, Osteoporosis International.
[5] H. Jha,et al. Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay , 2005, British Journal of Nutrition.
[6] B. Hollis. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. , 2005, The Journal of nutrition.
[7] J. McGrath,et al. Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.
[8] Yan Zhu,et al. Calcium and 1α,25‐dihydroxyvitamin D3 target the TNF‐α pathway to suppress experimental inflammatory bowel disease , 2005 .
[9] Yan Zhu,et al. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. , 2005, European journal of immunology.
[10] Steven A. Smith,et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. , 2005, Journal of chemical neuroanatomy.
[11] P. Rothwell,et al. Timing of birth and risk of multiple sclerosis: population based study , 2004, BMJ : British Medical Journal.
[12] M. Cantorna,et al. Mounting Evidence for Vitamin D as an Environmental Factor Affecting Autoimmune Disease Prevalence , 2004, Experimental biology and medicine.
[13] A. Sadovnick,et al. Vitamin D intake and incidence of multiple sclerosis , 2004, Neurology.
[14] Jonne Vaarno,et al. Fluorescent nanoparticles as labels for immunometric assay of C-reactive protein using two-photon excitation assay technology. , 2004, Analytical biochemistry.
[15] H. Suominen,et al. Vitamin D status as a determinant of peak bone mass in young Finnish men. , 2004, The Journal of clinical endocrinology and metabolism.
[16] M. Uskoković,et al. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. , 2004, Journal of cellular biochemistry.
[17] T. Dwyer,et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study , 2003, BMJ : British Medical Journal.
[18] M. Uskoković,et al. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases , 2003 .
[19] M. Hakama,et al. Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses , 2003, Journal of neurology, neurosurgery, and psychiatry.
[20] Elina Hyppönen,et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study , 2001, The Lancet.
[21] Richard A. C. Hughes,et al. PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.
[22] M. Välimäki,et al. A high prevalence of hypovitaminosis D in Finnish medical in‐ and outpatients , 2001, Journal of internal medicine.
[23] C. Hayes. Vitamin D: a natural inhibitor of multiple sclerosis , 2000, Proceedings of the Nutrition Society.
[24] R. Vieth,et al. Vitamin D and seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.
[25] C. Gössl,et al. Seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.
[26] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[27] E. Gunter,et al. Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.
[29] S. Ralston,et al. Nitric oxide and bone , 2001, Immunology.
[30] R. Sandyk,et al. Multiple sclerosis: relationship between seasonal variations of relapse and age of onset. , 1993, The International journal of neuroscience.
[31] A. Ziegler,et al. Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus. , 1991, Diabetes research.
[32] R. Williams,et al. Williams Textbook of endocrinology , 1985 .
[33] S. Manolagas,et al. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.
[34] M. Alter,et al. Multiple sclerosis and nutrition. , 1974, Archives of neurology.
[35] Kh G Khodos. [On the geography of multiple sclerosis]. , 1960, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova.
[36] M. Folan. Immunological Tolerance , 1956, Journal of the Irish Medical Association.
[37] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.